Acceleron pharma inc (XLRN)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11
Contract manufacturing

-

-

-

-

-

-

-

-

1,745

Revenues

73,993

13,991

13,481

27,771

18,097

14,632

57,230

15,254

80,911

Costs and expenses:
Research and Development Expense

153,953

103,902

89,726

68,580

58,404

50,897

36,051

35,319

32,713

Selling, general and administrative

56,485

34,503

33,738

25,297

20,572

14,199

14,227

8,824

8,142

Litigation settlement

-

-

-

-

-

5,000

0

0

-

Cost of contract manufacturing revenue

-

-

-

-

-

-

-

-

1,500

Total costs and expenses

210,438

138,405

123,464

93,877

78,976

70,096

50,278

44,143

42,355

Loss from operations

-136,445

-124,414

-109,983

-66,106

-60,879

-55,464

6,952

-28,889

38,556

Other income (expense):
Other income (expense), net

819

-52

-992

7,262

-3,527

5,044

-26,797

-2,255

-485

Interest income

10,706

5,568

2,553

1,854

512

83

39

91

17

Interest expense

-

-

-

-

-

922

2,092

1,529

1,822

Other income, net

11,525

5,516

1,561

9,116

-3,015

4,205

-28,850

-3,693

-2,290

Loss before income taxes

-124,920

-118,898

-108,422

-56,990

-63,894

-51,259

-

-

-

Income tax provision

-62

-27

32

24

0

0

-

-

-

Net Income (Loss) Attributable to Parent

-124,858

-118,871

-108,454

-57,014

-63,894

-51,259

-21,898

-32,582

36,266

Net loss applicable to participating securities

-

-

-

-

-

-

-

-

12,395

Net loss applicable to common stockholdersbasic and diluted

-

-

-

-

-

-

-

-

2,114

Net income (loss) per share applicable to common stockholders:
Basic (in dollars per share)

-

-

-

-

-

-

-

-

0.80

Diluted (in dollars per share)

-

-

-

-

-

-

-

-

0.78

Weighted-average number of common shares used in computing net loss per share applicable to common stockholders:
Basic (in shares)

-

-

-

-

-

-

-

-

2,328

Diluted (in shares)

-

-

-

-

-

-

-

-

2,716

Other comprehensive (loss) income:
Accretion of dividends, interest, redemption value and issuance costs on redeemable convertible preferred stock

-

-

-

-

-

-

19,870

27,061

21,757

Gain on extinguishment of redeemable convertible preferred stock

-

-

-

-

-

-

2,765

0

-

Net loss applicable to participating securities

-

-

-

-

-

-

-

-

12,645

Net (loss) income applicable to common stockholders-basic and diluted

-

-

-

-

-

-

-39,003

-59,643

1,864

Net (loss) income

-124,858

-118,871

-108,454

-57,014

-63,894

-

-21,898

-32,582

36,266

Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax

583

335

-470

-205

-220

0

0

-

-

Comprehensive loss

-124,275

-118,536

-108,924

-57,219

-64,114

-51,259

-21,898

-32,582

36,266

Net loss per share- basic and diluted (in dollars per share)

-2.38

-2.59

-2.68

-1.52

-1.92

-1.63

-4.15

-24.84

-

Weighted-average number of common shares used in computing net loss per share- basic and diluted (in shares)

52,453

45,898

40,420

37,430

33,303

31,515

9,407

2,401

-

License and milestone
Revenue

60,000

0

541

15,549

1,184

1,673

43,948

9,696

74,406

Cost-sharing, net
Revenues

13,993

13,991

12,940

12,221

16,913

12,959

13,282

5,558

4,760